At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
BI 1015550drug
Likely dose
BI 1015550 24 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects
In Brief
A Phase 1 clinical trial evaluating BI 1015550 for Healthy. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The primary objective of this trial is to investigate the effect of food on the pharmacokinetics of the oral tablet formulation of BI 1015550 by investigating the relative bioavailability of TF1 under fed and fasted conditions. The assessment of safety and tolerability will be an additional objective of this part.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartOct 2017
Primary CompletionDec 2017
TodayJul 2026
First PostedOct 4, 2017
Enrollment StartOct 16, 2017
Primary CompletionDec 13, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.7 years ago
Interventions
BI 1015550drug
Single dose of BI 1015550 4x6 mg (24 mg) tablets under fed or fasted condition